<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1310211166
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IROREST FCT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEFERASIROX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        180
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1044
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX RESEARCH PRIVATE LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX RESEARCH PRIVATE LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What IROREST FCT is:</strong></p><p>IROREST FCT contains an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload). It traps and removes excess iron which is then excreted mainly in the stools.</p><p>&nbsp;</p><p><strong>What IROREST FCT is used for :</strong></p><p>Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can cause a build-up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions. In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medicines called <em>iron chelators </em>are used to remove the excess iron and reduce the risk of it causing organ damage.</p><p>&nbsp;</p><p>IROREST FCT is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.</p><p>&nbsp;</p><p>IROREST FCT is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.</p><p>&nbsp;</p><p>IROREST FCT is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take IROREST FCT:</strong></p><ul><li>if you are allergic to deferasirox or any of the other ingredients of this medicine (listed in section 6). If this applies to you, <strong>tell your doctor before taking IROREST FCT</strong>. If you think you may be allergic, ask your doctor for advice.</li><li>if you have moderate or severe kidney disease.</li><li>if you are currently taking any other iron chelator medicines.</li></ul><p>&nbsp;</p><p><strong>IROREST FCT is not recommended:</strong></p><ul><li>if you are at an advanced stage of myelodysplastic syndrome (MDS; decreased production of blood cells by the bone marrow) or have advanced cancer.</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor or pharmacist before taking IROREST FCT: </strong></p><ul><li>if you have a kidney or liver problem.</li><li>if you have a cardiac problem due to iron overload.</li><li>if you notice a marked decrease in your urine output (sign of kidney problem).</li><li>if you develop a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction, see also section 4 &ldquo;Possible side effects&rdquo;).</li><li>if you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes (signs of severe skin reaction, see also section 4 &ldquo;Possible side effects&rdquo;).</li><li>if you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems).</li><li>if you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems, see also section 4 &ldquo;Possible side effects&rdquo;).</li><li>if you vomit blood and/or have black stools.</li><li>if you experience frequent abdominal pain, particularly after eating or taking IROREST FCT.</li><li>if you experience frequent heartburn.</li><li>if you have a low level of platelets or white blood cells in your blood test.</li><li>if you have blurred vision</li><li>if you have diarrhoea or vomiting.</li></ul><p>If any of these apply to you, tell your doctor straight away.</p><p><strong>&nbsp;</strong></p><p><strong>Monitoring your IROREST FCT treatment:</strong></p><p>You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of <em>ferritin</em>) to see how well IROREST FCT is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). Your doctor may require you to undergo a kidney biopsy, if he/she suspects significant kidney damage. You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of IROREST FCT most suitable for you and will also use these tests to decide when you should stop taking IROREST FCT.</p><p>&nbsp;</p><p>Your eyesight and hearing will be tested each year during treatment as a precautionary measure.</p><p>&nbsp;</p><p><strong>Other medicines and IROREST FCT:</strong></p><p><strong>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular:</strong></p><ul><li>other iron chelators, which must not be taken with IROREST FCT,</li><li>antacids (medicines used to treat heartburn) containing aluminium, which should not be taken at the same time of day as IROREST FCT,</li><li>ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis),</li><li>simvastatin (used to lower cholesterol),</li><li>certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids),</li><li>oral bisphosphonates (used to treat osteoporosis),</li><li>anticoagulant medicines (used to prevent or treat blood clotting),</li><li>hormonal contraceptive agents (birth control medicines),</li><li>bepridil, ergotamine (used for heart problems and migraines),</li><li>repaglinide (used to treat diabetes),</li><li>rifampicin (used to treat tuberculosis),</li><li>phenytoin, phenobarbital, carbamazepine (used to treat epilepsy),</li><li>ritonavir (used in the treatment of HIV infection),</li><li>paclitaxel (used in cancer treatment),</li><li>theophylline (used to treat respiratory diseases such as asthma),</li><li>clozapine (used to treat psychiatric disorders such as schizophrenia),</li><li>tizanidine (used as a muscle relaxant),</li><li>cholestyramine (used to lower cholesterol levels in the blood),</li><li>busulfan (used as a treatment prior to transplantation in order to destroy the original bone marrow before the transplant),</li><li>midazolam (used to relieve anxiety and/or trouble sleeping).</li><li>&nbsp;</li></ul><p>Additional tests may be required to monitor the blood levels of some of these medicines.</p><p><strong>&nbsp;</strong></p><p><strong>Older people (age 65 years and over):</strong></p><p>IROREST FCT can be used by people aged 65 years and over at the same dose as for other adults. Elderly patients may experience more side effects (in particular diarrhoea) than younger patients. They should be monitored closely by their doctor for side effects that may require a dose adjustment.</p><p>&nbsp;</p><p><strong>Children and adolescents:</strong></p><p>IROREST FCT can be used in children and adolescents receiving regular blood transfusions aged 2 years and over and in children and adolescents not receiving regular blood transfusions aged 10 years and over. As the patient grows the doctor will adjust the dose.</p><p>&nbsp;</p><p>IROREST FCT is not recommended for children aged under 2 years.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding:</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>IROREST FCT is not recommended during pregnancy unless clearly necessary.</p><p>If you are currently using a hormonal contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom), as IROREST FCT may reduce the effectiveness of hormonal contraceptives.</p><p>Breast-feeding is not recommended during treatment with IROREST FCT.</p><p><strong>Driving and using machines </strong></p><p>If you feel dizzy after taking IROREST FCT, do not drive or operate any tools or machines until you are feeling normal again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with IROREST FCT will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions.</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much IROREST FCT to take:</strong></p><p>The dose of IROREST FCT is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day.</p><ul><li>The usual daily dose for IROREST FCT film-coated tablets at the start of the treatment for patients receiving regular blood transfusions is 14 mg per kilogram body weight. A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.</li><li>&nbsp;The usual daily dose for IROREST FCT film-coated tablets at the start of the treatment for patients not receiving regular blood transfusions is 7 mg per kilogram body weight.</li><li>&nbsp;Depending on how you respond to treatment, your doctor may later adjust your treatment to a higher or lower dose.</li><li>&nbsp;The maximum recommended daily dose for IROREST FCT film-coated tablets is:</li><li>28 mg per kilogram body weight for patients receiving regular blood transfusions,</li><li>14 mg per kilogram body weight for adult patients not receiving regular blood transfusions,</li><li>7 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions.</li></ul><p>&nbsp;</p><p>Deferasirox is also available as dispersible tablets. If you are switching from such dispersible tablets to IROREST FCT film-coated tablets, your dose will change. Your doctor will calculate the dose you need and tell you how many film-coated tablets to take each day.</p><p>&nbsp;</p><p><strong>When to take IROREST FCT:</strong></p><ul><li>Take IROREST FCT once a day, every day, at about the same time each day with some water.</li><li>Take IROREST FCT film-coated tablets either on an empty stomach or with a light meal.</li></ul><p>&nbsp;</p><p>Taking IROREST FCT at the same time each day will also help you remember when to take your tablets.</p><p>&nbsp;</p><p>For patients who are unable to swallow whole tablets, IROREST FCT film-coated tablets may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple). The food should be immediately and completely consumed. Do not store it for future use.</p><p>&nbsp;</p><p><strong>How long to take IROREST FCT:</strong></p><p><strong>Continue taking IROREST FCT every day for as long as your doctor tells you. </strong>This is a long-term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect (see also section 2: &ldquo;Monitoring your IROREST FCT treatment&rdquo;).</p><p>&nbsp;</p><p>If you have questions about how long to take IROREST FCT, talk to your doctor.</p><p>&nbsp;</p><p><strong>If you take more IROREST FCT than you should:</strong></p><p>If you have taken too much IROREST FCT, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away. Show the doctor the pack of tablets. Urgent medical treatment may be necessary. You may experience effects such as abdominal pain, diarrhoea, nausea and vomiting and kidney or liver problems that can be serious.</p><p>&nbsp;</p><p><strong>If you forget to take IROREST FCT:</strong></p><p>If you miss a dose, take it as soon as you remember on that day. Take your next dose as scheduled. Do not take a double dose on the next day to make up for the forgotten tablet(s).</p><p>&nbsp;</p><p><strong>If you stop taking IROREST FCT:</strong></p><p>Do not stop taking IROREST FCT unless your doctor tells you to. If you stop taking it, the excess iron will no longer be removed from your body (see also above section &ldquo;How long to take IROREST FCT&rdquo;).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.</p><p>&nbsp;</p><p><strong>Some side effects could be serious and need immediate medical attention.:</strong></p><p><em>These side effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people):</em></p><ul><li>If you get a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction),</li><li>If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes, (signs of severe skin reactions),</li><li>If you notice a marked decrease in your urine output (sign of kidney problem),</li><li>If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems),</li><li>If you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems and lead to a change in your brain function),</li><li>If you vomit blood and/or have black stools,</li><li>If you experience frequent abdominal pain, particularly after eating or taking IROREST FCT,</li><li>If you experience frequent heartburn,</li><li>If you experience partial loss of vision,</li></ul><p>If you experience severe upper stomach pain (pancreatitis),</p><p><strong>If you experience any of these side effects, stop taking this medicine and tell your doctor straight away.</strong></p><p><strong>Some side effects could become serious.</strong></p><p><em>&nbsp;</em></p><p><em>These side effects are uncommon:</em></p><ul><li>If you get blurred or cloudy eyesight,</li><li>If you get reduced hearing,</li></ul><p><strong>If you experience any of these side effects, tell your doctor as soon as possible.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other side effects:</strong></p><p><em>Very common (may affect more than 1 in 10 people):</em></p><ul><li>Disturbance in kidney function tests.</li></ul><p>&nbsp;</p><p><em>Common (may affect up to 1 in 10 people):</em></p><ul><li>Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating, constipation, indigestion</li><li>Rash</li><li>Headache</li><li>Disturbance in liver function tests</li><li>Itching</li><li>Disturbance in urine test (protein in the urine)</li></ul><p><strong>If any of these affects you severely, tell your doctor.</strong></p><p><em>&nbsp;</em></p><p><em>Uncommon (may affect up to 1 in 100 people):</em></p><ul><li>Dizziness</li><li>Fever</li><li>Sore throat</li><li>Swelling of arms or legs</li><li>Change in the colour of the skin</li><li>Anxiety</li><li>Sleep disorder</li><li>Tiredness</li></ul><p><strong>If any of these affects you severely, tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><em>Frequency not known (cannot be estimated from the available data):</em></p><ul><li>A decrease in the number of cells involved in blood clotting (thrombocytopenia), in the number of red blood cells (anaemia aggravated), in the number of white blood cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)</li><li>Hair loss</li><li>Kidney stones</li><li>Low urine output</li><li>Tear in stomach or intestine wall that can be painful and cause nausea</li><li>Severe upper stomach pain (pancreatitis)</li><li>Abnormal level of acid in blood<p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p><strong>Saudi Arabia</strong><strong>:</strong><br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>The National Pharmacovigilance Centre (NPC)</strong><strong>:</strong></p><ul><li>Fax: +966-11-205-7662</li><li>SFDA Call Centre: 19999</li><li>E-mail: npc.drug@sfda.gov.sa&nbsp;</li><li>Website: https://ade.sfda.gov.sa&nbsp;</li></ul></td></tr></tbody></table><p><br /><strong>United Arab Emirates:</strong><br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>Pharmacovigilance &amp; Medical Device Section</strong></p><ul><li>P.O.Box: 1853</li><li>Tel: 80011111</li><li>Email : pv@ede.gov.ae</li></ul><p><strong>Drug Department</strong></p><p><strong>Ministry of Health &amp; Prevention</strong></p><strong>Dubai</strong></td></tr></tbody></table><p><br /><strong>Other GCC Countries:</strong><br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p><br /><strong>Council of Arab Health Ministers Warning:</strong></p></li><li><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong><u>This is a Medicament </u></strong></p><ul><li>Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</li><li>Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</li><li>The doctor and the pharmacist are the experts in medicines, their benefits and risks.</li><li>Do not by yourself interrupt the period of treatment prescribed for you.</li><li>Do not repeat the same prescription without consulting your doctor.</li><li>Keep all medicaments out of reach of children.</li></ul><p><strong>Council of Arab Health Ministers</strong></p></td></tr></tbody></table><strong>Union of Arab Pharmacists</strong></td></tr></tbody></table><p>&nbsp;</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Do not use IROREST FCT after the expiry date which is stated on the package/carton after EXP. The expiry date refers to the last day of that month.</li><li>Store below 30&deg;C. Protect from moisture.</li><li>Store in the original package.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What IROREST FCT contains:</strong></p><p>&nbsp;</p><p><u>Medicinal ingredients are: </u></p><p>The active substances is deferasirox 90 mg, 180 mg or 360 mg per tablet.</p><p>&nbsp;</p><p><u>Non-medicinal ingredients are: </u></p><p>Colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, indigotine Al Lake 12-14%, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What dosage form IROREST FCT comes in:

•	IROREST FCT is supplied as film-coated tablets. Each tablet contains 90 mg, 180 mg or 360 mg deferasirox.
•	IROREST FCT is supplied in blisters of 30 film-coated tablets (3 blisters of 10 tablets per box).

What IROREST FCT looks like:

90 mg
White to light blue colored, modified capsule-shaped, film-coated tablet engraved ‘APO’ on one side and ‘DF 90’ on the other side.
180 mg
Blue to medium blue colored, modified capsule-shaped, film-coated tablet engraved ‘APO’ on one side and ‘DF 180’ on the other side.
360 mg
Blue to dark blue colored, modified capsule-shaped film coated-tablet engraved ‘APO’ on one side and ‘DF 360’ on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Apotex Inc</p><p>150 Signet Drive</p><p>Toronto, Ontario</p><p>Canada, M9L 1T9</p><p>Tel: 1-800-268-4623, Fax: 1-800-609-9444</p><p>www.apotex.com</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer:</strong></p><p>Apotex Research Private Limited,</p><p>Plot 1 and 2 Bommasandra Industrial Area,</p><p>4th Phase, Jigani link road,</p><p>Bangalore 560 099,</p><p>Karnataka, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised: 07/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <ul dir="rtl"><li><strong>ما هو دواء آيرورست </strong><strong>FCT:</strong></li></ul><p dir="RTL">يحتوي آيرورست FCT على مادة فعالة تسمى ديفيراسيروكس وهي مادة خالبة للحديد تستخدم كدواء لإزالة الحديد الفائض عن حاجة الجسم (يسمى ذلك أيضًا فرط حمل الحديد). وهي تحتجز الحديد الفائض عن حاجة الجسم وتزيله ثم تخرجه بصفة رئيسية في البراز.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استعماله:</strong></p><p dir="RTL">قد يكون نقل الدم المتكرر ضروريًّا للمرضى بأنواع مختلفة لفقر الدم (مثل أنيميا البحر المتوسط، وداء الخلايا المنجلية أو متلازمة خلل التنسج النقوي (MDS). ولكن، يمكن أن يسبب نقل الدم المتكرر تراكماً للحديد الفائض عن حاجة الجسم. يرجع ذلك لأن الدم يحتوي على حديد، ولا تتوفر لجسمك طريقة طبيعية لإزالة الحديد الفائض عن حاجته الذي تحصل عليه من نقل الدم لك. في مرضى متلازمات أنيميا البحر المتوسط غير المعتمدة على (نقل الدم)،&nbsp;قد يحدث فرط حمل الحديد كذلك بمرور الوقت، وخاصةً نتيجة زيادة امتصاص الحديد من الطعام استجابةً لانخفاض تعدادات خلايا الدم. بمرور الوقت، يمكن للحديد الفائض عن حاجة الجسم أن يضر بأعضاء مهمة كالكبد والقلب. تستخدم أدوية تسمى&nbsp;خالبات الحديد&nbsp;لإزالة الحديد الفائض والحد من خطر تسببه في الإضرار بأعضاء الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم آيرورست FCT لعلاج فرط حمل الحديد المزمن الناتج عن نقل الدم المتواتر في المرضى المصابين بأنيميا البحر المتوسط الكبرى من النوع بيتا ممن تبلغ أعمارهم 6 سنوات فما فوق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم آيرورست FCT كذلك في علاج فرط حمل الحديد المزمن عندما يكون العلاج باستخدام ديفيروكزامين ممنوعًا أو غير مناسب في المرضى المصابين بأنيميا البحر المتوسط الكبرى من النوع بيتا المصابين بفرط حمل الحديد بسبب نقل الدم على فترات متباعدة، وفي المرضى المصابين بأنواع أخرى لفقر الدم، وفي الأطفال الذين تتراوح أعمارهم بين 2-5 سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم آيرورست FCT كذلك عندما يكون العلاج باستخدام ديفيروكزامين ممنوعًا أو غير مناسب لعلاج المرضى الذين تبلغ أعمارهم 10 سنوات أو أكبر عندما يصاحب فرط حمل الحديد إصابتهم بمتلازمات البحر المتوسط، وإن كانوا غير معتمدين على نقل الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>موانع استعمال آيرورست </u></strong><strong><u>FCT:</u></strong></p><ul dir="rtl"><li>إن كنت مصابًا بالحساسية تجاه ديفيراسيروكس أو أي من المكونات الأخرى لهذا الدواء (مسرودة في القسم 6). إن كان ذلك ينطبق عليك،&nbsp;<strong>فأبلغ طبيبك&nbsp; قبل تناول آيرورست </strong><strong>FCT.</strong>&nbsp;إن كنت تشك في أنك مصاب بالحساسية، فاستشر الطبيب.</li><li>إن كنت مصابًا بمرض كلوي معتدل أو شديد.</li><li>إن كنت تتلقى حاليًّا أية أدوية أخرى خالِبة للحديد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>لا يوصى بدواء آيرورست </u></strong><strong><u>FCT:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بمرحلة متقدمة لمتلازمة خلل التنسج النقوي (MDS: نقص إنتاج النخاع العظمي لخلايا الدم) أو بسرطان متقدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الاحتياطات عند استعمال آيرورست </u></strong><strong><u>FCT:</u></strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>ينبغي استشارة الطبيب أو الصيدلي قبل استخدام آيرورست </strong><strong>FCT:</strong></p><ul dir="rtl"><li>إن كنت مصابًا بمشكلة قلبية بسبب فرط حمل الحديد.</li><li>إن لاحظت نقصًا لافتًا لناتجك البولي (علامة على مشكلة كلوية).</li><li>إن أصبت بطفح جلدي شديد، أو صعوبة التنفس، أو الدوخة، أو التورم وخاصةً في الوجه والحلق (علامات على رد فعل حساسي شديد، انظر كذلك القسم 4 &quot;الآثار الجانبية الممكنة&quot;).</li><li>إن أصبت &nbsp;بمزيج من الأعراض التالية: طفح جلدي ,احمرار الجلد، أو تقرح الشفتين، أو العينين أو الفم، أو تقشر الجلد، أو الحمى الشديدة , أعراض تشبه أعراض الإنفلونزا, تضخم الغدد اللمفاوية (علامات على رد فعل جلدي شديد، انظر كذلك القسم 4 &quot;الآثار الجانبية الممكنة&quot;).</li><li>إن أصبت بمزيج من الدوخة، والألم في الجزء العلوي الأيمن للبطن، واصفرار أو زيادة اصفرار جلدك أو عينيك أو البول الداكن (علامات على مشكلات كبدية).</li><li>إذا أًصبت بصعوبة في التفكير، تذكر المعلومات أو حل المشكلات، أصبحت أقل تيقظاً أو وعي أو شعور بالنعاس الشديد مصاحبًا انخفاض في النشاط ( علامات في إرتفاع نسبة الأمونيا في الدم، مما قد يصاحبه أمراض في الكبد و الكلى، انظر قسم 4 &quot; الأعراض الجانبية&quot;)</li><li>إن قئت دمًا و/ أو اسودَّ برازك.</li><li>إن أصبت بألم متواتر في البطن، وخاصةً بعد الأكل أو تناول آيرورست FCT.</li><li>إن أصبت بحرقة في المعدة المتواترة.</li><li>إن أصبت بنقص مستوى الصفيحات أو كريات الدم البيضاء في اختبار الدم الخاص بك.</li><li>إن أصبت بتشوش الإبصار.</li><li>إن أصبت بالإسهال أو القيء.</li><li>إن كان أي مما سبق ينطبق عليك، فأبلغ طبيبك فورًا.</li><li>&nbsp;</li></ul><p dir="RTL"><strong>مراقبة علاجك باستخدام آيرورست </strong><strong>FCT:</strong></p><p dir="RTL">ستخضع لاختبارات منتظمة للدم والبول خلال العلاج. يهدف ذلك إلى مراقبة كمية الحديد في جسمك (مستوى&nbsp;<em>فيريتين</em>&nbsp;في الدم) لملاحظة مدى كفاءة أداء آيرورست FCT. ستراقب تلك الاختبارات كذلك وظيفتك الكلوية (مستوى الكرياتينين في الدم، ووجود البروتين في البول)، ووظيفتك الكبدية (مستوى ناقلات الأمين في الدم). قد يطلب منك الطبيب الخضوع لخزعة كلوية، إن كان هو/ هي يشتبه في ضرر كلوي لافت. قد تخضع كذلك لاختبارات بأشعة الرنين المغناطيسي (MRI) لتحديد كمية الحديد في كبدك. سيضع طبيبك تلك الاختبارات في الاعتبار عندما يحدد جرعة آيرورست FCT الأنسب لك، وسيستخدم تلك الاختبارات كذلك لاتخاذ قراره بخصوص موعد إيقاف تناولك آيرورست FCT.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستجرى اختبارات لبصرك وسمعك كل سنة خلال العلاج كإجراء احترازي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى:</u></strong></p><p dir="RTL"><strong>أبلغ الطبيب أو الصيدلي إن كنت تستخدم، أو إن استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى. يتضمن ذلك على وجه الخصوص ما يلي:</strong></p><ul dir="rtl"><li>خالبات أخرى للحديد، ولا يجب تناولها أبدًا مع آيرورست FCT،</li><li>مضادات الحموضة (الأدوية المستخدمة لعلاج حرقة المعدة) التي تحتوي الألومونيوم، ولا يجب تناولها في نفس الموعد اليومي لتناولك آيرورست FCT،</li><li>سيكلوسبورين (يستخدم لمنع رفض الجسم للأعضاء المزروعة أو غير ذلك من الحالات، مثل التهاب المفاصل الروماتويدي أو التهاب الجلد التأتبي)،</li><li>سيمفاستاتين (يستخدم لخفض الكولسترول)،</li><li>بعض المسكنات أو الأدوية المضادة للالتهاب (مثل الأسبرين، وآيبوبروفين، والستيرويدات القشرية)،</li><li>أدوية البيسفوسفونيت الفموية (تستخدم لعلاج هشاشة العظام)،</li><li>الأدوية المضادة للتجلط (تستخدم لمنع تجلط الدم وعلاجه)،</li><li>عقاقير منع الحمل الفموية (أدوية منع الحمل)،</li><li>بيبريديل، وإيرجوتامين (يستخدمان لعلاج مشكلات القلب والصداع النصفي)،&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>ريباجلينيد (يستخدم لعلاج السكري)،</li><li>ريفامبيسين (يستخدم لعلاج الدرن)،</li><li>فينيتوين، وفينوباربيتال، وكاربامازيبين (تستخدم لعلاج الصرع)،</li><li>ريتونافير (يستخدم لعلاج عدوى العوز المناعي البشري)،</li><li>باكليتاكسيل (يستخدم لعلاج السرطان)،</li><li>ثيوفيللين (يستخدم لعلاج الأمراض التنفسية كالربو)،</li><li>كلوزابين (يستخدم لعلاج الاضطرابات النفسية مثل الفصام)،</li><li>تيزانيدين (يستخدم كمرخٍّ للعضلات)،</li><li>كوليستيرامين (يستخدم لخفض مستويات الكولسترول في الدم).</li><li>بوسلفان ( يستخدم كعلاج لزراعة الأعضاء من خلال تدمير النخاع العظمي الأساسي قبل عملية الزراعة)</li><li>الميدازولام (يستخدم لتخفيف القلق و/أو صعوبة النوم).</li></ul><p dir="RTL">قد تُطلب اختبارات إضافية لمراقبة مستويات بعض هذه الأدوية في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>&nbsp;المسنون (من تبلغ أعمارهم 65 فما فوق):</u></strong></p><p dir="RTL">يمكنك استخدام آيرورست FCT إن كان عمرك 65 عامًا فما فوق بنفس جرعة البالغين الآخرين. يمكن أن يصاب المرضى المسنون بأعراض جانبية أكثر (وخاصةً الإسهال) بالمقارنة بالمرضى الأصغر سنًّا. يجب أن يراقبهم الطبيب بعناية لأي آثار جانبية قد تتطلب تعديل الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>&nbsp;الأطفال واليافعون:</u></strong></p><p dir="RTL">يمكن استخدام آيرورست FCT في الأطفال والمراهقين ممن يتلقون نقل الدم بانتظام وتبلغ أعمارهم عامين فما فوق، وفي الأطفال والمراهقين الذين لا يتلقون نقل الدم بانتظام وتبلغ أعمارهم 10 سنوات فما فوق. سيعدل الطبيب الجرعة مع نمو المريض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يوصى باستخدام آيرورست FCT للأطفال الذين تقل أعمارهم عن عامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الحمل والرضاعة:</u></strong></p><p dir="RTL">إن كنتِ حاملًا أو مرضعة، أو تشكين أنك حامل أو تخططين للإنجاب، فاستشيري طبيبك قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يوصى باستخدام آيرورست FCT خلال الحمل ما لم تتضح ضرورة ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كنتِ تستخدمين حاليًّا إحدى وسائل منع الحمل الفموية، أو تستخدمين لصقة لمنع الحمل، فينبغي أن تستخدمي مانع حمل إضافيًّا أو من نوع مختلف (كالعازل)؛ حيث إن آيرورست FCT قد يحد فاعلية موانع الحمل الفموية ولصقات منع الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يوصى بالرضاعة الطبيعية خلال العلاج باستخدام آيرورست FCT.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>تأثير</u></strong><u>&nbsp;<strong>آيرورست </strong></u><strong><u>FCT على القيادة واستخدام الآلات:</u></strong></p><p dir="RTL">إن شعرت بالدوخة بعد تناول آيرورست FCT، فلا تقم بقيادة المركبات أو استخدام أية أدوات أو آلات حتى تشعر باستعادتك عافيتك مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيشرف طبيبك على العلاج باستخدام آيرورست FCT وهو خبير بعلاج فرط حمل الحديد الناتج عن نقل الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">دائمًا ينبغي تناول هذا الدواء حسب إرشادات الطبيب تمامًا. راجع طبيبك أو الصيدلي إن كنت في شك من ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما جرعة دواء آيرورست </strong><strong>FCT التي يجب أخذها؟</strong></p><p dir="RTL">ترتبط جرعة آيرورست FCT بوزن الجسم لجميع المرضى. سيحسب طبيبك الجرعة التي تحتاجها، وسيبلغك بعدد الأقراص التي ينبغي تناولها يوميًّا.</p><ul dir="rtl"><li>تبلغ الجرعة اليومية المعتادة من (أقراص آيرورست FCT المغلفة) في بداية العلاج للمرضى الذين يتلقون نقل الدم بانتظام 14 ملجم لكل كيلوجرام من وزن الجسم. قد يوصى الطبيب بجرعة أكثر أو أقل بناءً على احتياجاتك العلاجية الفردية.</li><li>تبلغ الجرعة اليومية المعتادة من (أقراص آيرورست FCT المغلفة) في بداية العلاج للمرضى الذين لا يتلقون نقل الدم بانتظام 7 ملجم لكل كيلوجرام من وزن الجسم.</li><li>بحسب كيفية استجابتك للعلاج، فقد يقوم الطبيب لاحقًا بتعديل علاجك إلى جرعة أكثر أو أقل.</li><li>الجرعة اليومية القصوى الموصى بها من أقراص آيرورست FCT المغلفة هي:</li></ul><p>- 28 ملجم لكل كيلوجرام من وزن الجسم للمرضى الذين يتلقون نقل الدم بانتظام.</p><p>- 14 ملجم لكل كيلوجرام من وزن الجسم للمرضى البالغين الذين لا يتلقون نقل الدم بانتظام.</p><p>- 7 ملجم لكل كيلوجرام من وزن الجسم الأطفال و المراهقين &nbsp;الذين لا يتلقون نقل الدم بانتظام.</p><p>&nbsp;</p><p dir="RTL">يتوفر ديفيراسيروكس أيضاً كأقراص &quot;فوّارة&quot;. إن انتقلت من استخدام الأقراص الفوارة لهذه الأقراص المغلفة، فستحتاج لتعديل الجرعة. سيحسب طبيبك الجرعة التي تحتاجها ويخبرك بعدد الأقراص المغلفة التي يجب تناولها كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية تناول آيرورست </strong><strong>FCT:</strong></p><ul dir="rtl"><li>تناول آيرورست FCT مرة يوميًّا، كل يوم، في نفس التوقيت يوميًّا مع بعض الماء.</li><li>تناول أقراص آيرورست FCT المغلفة إما على معدة خاوية أو مع وجبة خفيفة.</li></ul><p dir="RTL">استخدام آيرورست FCT في نفس التوقيت يوميًّا سيساعدك كذلك أن تتذكر موعد تناول أقراصك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن لم يكن باستطاعة المرضى بلع الأقراص كاملةً، فيمكن تهشيم أقراص آيرورست FCT المغلفة وتناولها عن طريق نثر الجرعة كاملة على طعام لين كالزبادي أو صوص التفاح (التفاح المهروس). يجب تناول الطعام فورًا وبكامله. لا تخزنه للاستخدام لاحقًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي مدة العلاج بآيرورست </strong><strong>FCT</strong>؟</p><p dir="RTL"><strong>واظب على تناول آيرورست </strong><strong>FCT يوميًّا للفترة التي يبلغك بها طبيبك.</strong>&nbsp;هذا علاج طويل الأمد، وقد يستمر لشهور أو لسنوات. سيراقب طبيبك حالتك بانتظام للتأكد أن للعلاج أثره المرجو (انظر كذلك القسم 2: &quot;مراقبة علاجك باستخدام آيرورست FCT&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كانت لديك أسئلة بخصوص مدة استخدامك آيرورست FCT، فاستشر الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت جرعة زائدة من آيرورست </strong><strong>FCT:</strong></p><p dir="RTL">إن تناولت بالخطأ أقراصًا أكثر مما ينبغي لك، أو إن تناول شخص آخر أقراصك عن طريق الخطأ، فاتصل بالطبيب أو المستشفى طلبًا للنصيحة فورًا. أرهم علبة الأقراص. قد يستدعي ذلك علاجًا طبيًّا. قد تشعر بآلام البطن والإسهال والغثيان والقيء ومشاكل في الكلى أو الكبد يمكن أن تكون خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسي</strong><strong>ت تناول جرعة من آيرورست </strong><strong>FCT:</strong></p><p dir="RTL">إن نسيت إحدى الجرعات، فتناولها فور تذكرها في ذلك اليوم. تناول جرعتك التالية في موعدها المحدد. لا تتناول جرعة مزدوجة لتعويض القرص المنسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول آيرورست </strong><strong>FCT:</strong></p><p dir="RTL">لا توقف تناول آيرورست FCT ما لم يبلغك طبيبك بذلك. إن أوقفت تناوله، فإن الحديد الفائض لن يزال من جسمك (انظر كذلك القسم المسرود أعلاه &quot;كم مدة تناول آيرورست FCT&quot;).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، وإن كانت لا تحدث في جميع الأشخاص الذين يتعاطونه. أغلب الآثار الجانبية بسيطة إلى معتدلة وستختفي بصفة عامة بعد بضعة أيام أو أسابيع من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تكون بعض الآثار الجانبية خطيرة وتحتاج عناية طبية فورية.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>هذه الآثار الجانبية غير شائعة (قد تصيب&nbsp;حتى شخصاً من بين 100 شخص) أو نادرة (قد تصيب&nbsp;حتى&nbsp;شخصاً من بين 1000 شخص).</u></p><ul dir="rtl"><li>إن أصبت بطفح جلدي شديد، أو صعوبة التنفس، أو الدوخة، أو التورم وخاصةً في الوجه والحلق (علامات على رد فعل حساسي شديد)،</li><li>إن أصبت &nbsp;بمزيج من الأعراض التالية: طفح جلدي ,احمرار الجلد، أو تقرح الشفتين، أو العينين أو الفم، أو تقشر الجلد، أو الحمى الشديدة , أعراض تشبه أعراض الإنفلونزا, تضخم الغدد اللمفاوية (علامات على رد فعل جلدي شديد، انظر كذلك القسم 4 &quot;الآثار الجانبية الممكنة&quot;).</li><li>&nbsp;</li><li>إن لاحظت نقصًا لافتًا لناتجك البولي (علامة على مشكلة كلوية)،</li><li>إن أصبت بمزيج من الدوخة، والألم في الجزء العلوي الأيمن للبطن، واصفرار أو زيادة اصفرار جلدك أو عينيك أو البول الداكن (علامات على مشكلات كبدية)،</li><li>إذا أًصبت بصعوبة في التفكير، تذكر المعلومات أو حل المشكلات، أصبحت أقل تيقظاً أو وعي أو شعور بالنعاس الشديد مصاحبًا انخفاض في النشاط ( علامات في إرتفاع نسبة الأمونيا في الدم، مما قد يصاحبه أمراض في الكبد و الكلى وتؤدي إلى تغيير في وظائف الدماغ)</li><li>إن قئت دمًا و/ أو اسودَّ برازك،</li><li>إن أصبت بألم متواتر في البطن، وخاصةً بعد الأكل أو تناول آيرورست FCT،</li><li>إن أصبت بحرقة المعدة المتواترة،</li><li>إن أصبت بضعف الإبصار المؤقت،</li><li>إن أصبت بألم شديد في الجزء العلوي من البطن (التهاب البنكرياس)،</li></ul><p dir="RTL"><strong>إن أصبت بأي من هذه الآثار الجانبية</strong><strong>، أوقف تناول هذا الدواء وأبلغ طبيبك فورًا.</strong></p><p dir="RTL"><strong>قد تصير بعض الأعراض الجانبية خطيرة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>هذه الآثار الجانبية غير شائعة:</u></p><ul dir="rtl"><li>&nbsp;إن أصبت بتشوش الإبصار أو ضبابيته،</li><li>إن أصبت بضعف السمع،</li></ul><p dir="RTL"><strong>إن أصبت بأي من هذه الآثار الجانبية</strong><strong>، أبلغ طبيبك في أقرب فرصة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى:</strong></p><p dir="RTL"><u>بالغة الشيوع (قد تصيب أكثر من شخص من بين 10 أشخاص):</u></p><ul dir="rtl"><li>إضطراب اختبارات الوظيفة الكلوية.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><u>شائعة (قد تصيب حتى&nbsp;شخصاً من بين 10 أشخاص):</u></p><ul dir="rtl"><li>اضطرابات الجهاز الهضمي، كالغثيان، والقيء، والإسهال، وألم البطن، والانتفاخ، والإمساك، وعسر الهضم</li><li>الطفح الجلدي</li><li>الصداع</li><li>اضطراب اختبارات الوظيفة الكبدية</li><li>الهرش</li><li>اضطراب في اختبار البول (بروتين في البول)</li></ul><p dir="RTL"><strong>إن أثر عليك أي من ذلك بشدة، فأبلغ طبيبك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير شائعة (قد تصيب&nbsp;حتى&nbsp;شخصاً من بين 100 شخص):</u></p><ul dir="rtl"><li>الدوخة</li><li>&nbsp;الحمى</li><li>&nbsp;ألم الحلق</li><li>تورم الذراعين أو الساقين</li><li>تغير لون الجلد</li><li>القلق</li><li>اضطراب النوم</li><li>الإرهاق</li></ul><p dir="RTL"><strong>إن أثر عليك أي من ذلك بشدة، فأبلغ طبيبك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>نسبة حصوله غير معروفة&nbsp;(لم يمكن تقديره من خلال البيانات المتاحة):</u></p><ul dir="rtl"><li>نقص عدد الخلايا المسؤولة عن تجلط الدم (نقص الصفيحات)، وعدد خلايا الدم الحمراء (تفاقم فقر الدم)، ونقص عدد خلايا الدم البيضاء (نقص الخلايا المتعادلة) أو عدد كل أنواع خلايا الدم (النقص الشامل لخلايا الدم)</li><li>&nbsp;تساقط الشعر</li><li>حصوات الكلى</li><li>&nbsp;نقص الناتج البولي</li><li>جرح في جدار المعدة أو الأمعاء، وقد يكون مؤلمًا ويسبب الغثيان</li><li>ألم شديد في الجزء العلوي من البطن (التهاب البنكرياس)</li><li>مستوى غير طبيعي للحمض في الدم</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ في درجة حرارة أقل من 30 درجة مئوية. ويُحفظ من الرطوبة.</p><p dir="RTL">يُحفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">يجب عدم استخدام الدواء بعد تاريخ انتهاء الصلاحية المُوضح على العبوة / العلبة بعد كلمة EXP. يُشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يُخزن في العبوة الأصلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على ماذا يحتوى آيرورست </strong><strong>FCT</strong><strong> </strong></p><p dir="RTL"><u>المكونات الطبية:</u></p><p dir="RTL">المادة الفعَّالة هي ديفيراسيروكس 90 ملجم، 180 ملجم أو 360 ملجم في كل قرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المكونات غير الطبية:</u></p><p dir="RTL">ثاني أكسيد السيليكون الغروي، كروسبوفيدون، هيدروكسي بروبيل السليلوز، هيدروكسي بروبيل ميثيل سلولوز، إنديجوتين آل ليك 12-14٪، ستيرات المغنيسيوم، السليلوز الجريزوفولفين، بولي إيثيلين جليكول، بولي سوربات 80، بوفيدون وثاني أكسيد التيتانيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:<br />المملكة العربية السعودية:</strong><br />&nbsp;</p><table cellspacing="0" cellpadding="0" align="right"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي </strong><strong>(NPC)</strong><strong>:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><ul dir="rtl"><li>فاكس: 7662-205-11-966 +</li><li>مركز اتصال الهيئة العامة للغذاء والدواء: 19999</li><li>البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li>&nbsp;الموقع: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p dir="RTL"><br /><strong>الامارات العربية المتحدة:</strong></p><table cellspacing="0" cellpadding="0" align="right"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>قسم التيقظ والسلامة والأجهزة الطبية </strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><ul dir="rtl"><li>صندوق بريد: 1853</li><li>الهاتف: 80011111</li><li>البريد الإلكتروني: pv@ede.gov.ae</li></ul><p dir="RTL"><strong>قسم الدواء</strong></p><p dir="RTL"><strong>وزارة الصحة ووقاية المجتمع</strong></p><p dir="RTL"><strong>دبي</strong></p></td></tr></tbody></table><p dir="RTL"><br /><br /><strong>دول مجلس التعاون الخليجي الأخرى:</strong><br />يُرجى الاتصال بالسلطة المختصة ذات الصلة.<br /><br /><strong>مجلس وزراء الصحة العرب:<br /><u>هذا دواء</u></strong></p><table cellspacing="0" cellpadding="0" align="right"><tbody><tr><td style="vertical-align:top"><ul dir="rtl"><li>الدواء هو منتج يؤثر على صحتك، واستهلاكه خلافًا للتعليمات يعرّضك للخطر.</li><li>اتبع بدقة وصفة الطبيب، وطريقة الاستخدام، وتعليمات الصيدلي الذي باع لك الدواء.</li><li>الطبيب والصيدلي هما الخبيران في الأدوية، وفوائدها ومخاطرها.</li><li>لا تقطع فترة العلاج الموصوفة لك من تلقاء نفسك.</li><li>لا تكرر نفس الوصفة بدون استشارة الطبيب.</li><li>احفظ جميع الأدوية بعيدًا عن متناول الأطفال.</li></ul><p><strong>مجلس وزراء الصحة العرب</strong></p></td></tr></tbody></table><p dir="RTL"><strong>اتحاد الصيادلة العرب</strong></p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>الشكل الصيدلاني</strong><strong> </strong><strong>للدواء:</strong></p><ul dir="rtl"><li style="text-align:right">يتوفر آيرورست FCT في صورة أقراص مغلفة يتم تناولها عن طريق الفم. يحتوي كلُّ قرصٍ على 90 ملجم أو 180 ملجم أو 360 ملجم من الديفيراسيروكس.</li><li style="text-align:right">&nbsp;تحتوي كلُّ عبوة على أشرطة بمجموع 30 قرص مغلف (ثلاثة أشرطة، كل شريط يحتوي على 10 أقراص مغلفة).</li></ul><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>كيف يبدو آيرورست </strong><strong>FCT</strong><strong>:</strong></p><ul dir="rtl"><li style="text-align:right"><strong>90 ملجم:</strong> قرص مطلي باللون الأبيض إلى الأزرق الفاتح، على شكل كبسولة معدلة، مُغطى بطبقة رقيقة محفور &ldquo;APO&rdquo; على جانب واحد و &ldquo;DF 90&rdquo; على الجانب الآخر.</li><li style="text-align:right"><strong>180</strong> <strong>ملجم</strong>: قرص مطلي باللون أزرق إلى أزرق متوسط، على شكل كبسولة معدلة، مُغطى بطبقة رقيقة محفور &ldquo;APO&rdquo; على جانب واحد و &ldquo;DF 180&rdquo; على الجانب الآخر.</li><li style="text-align:right"><strong>360</strong> <strong>ملجم</strong>: قرص مطلي باللون أزرق إلى أزرق داكن، على شكل كبسولة معدلة محفور، مُغطى بطبقة رقيقة &ldquo;APO&rdquo; على جانب واحد و &ldquo;DF 360&rdquo; على الجانب الآخر.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong><strong>:</strong></p><p dir="RTL">أبوتكس إنكوربوريتد</p><p dir="RTL">150 سيجنت درايف</p><p dir="RTL">تورونتو، أونتاريو</p><p dir="RTL">كندا، M9L 1T9</p><p dir="RTL">الهاتف: 4623-268-800-1، الفاكس: 9444-609-800-1</p><p dir="RTL">www.apotex.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنِّعة:</strong></p><p dir="RTL">أبوتكس للأبحاث الخاصة المحدودة</p><p dir="RTL">قطعة رقم 1 و 2، منطقة بوماساندرا الصناعية</p><p dir="RTL">المرحلة الرابعة، طريق جيجاني لينك</p><p dir="RTL">بنجالور 099 560،</p><p dir="RTL">كرناتكا، الهند</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تم إعداد هذه النشرة من قبل: أبوتكس إنك.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمّت مراجعتها في 07/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trade Name: IROREST FCT
Generic Name: Deferasirox
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                IROREST FCT 90 mg film-coated tablets
Each film-coated tablet contains 90 mg deferasirox.
IROREST FCT 180 mg film-coated tablets
Each film-coated tablet contains 180 mg deferasirox.
IROREST FCT 360 mg film-coated tablets
Each film-coated tablet contains 360 mg deferasirox.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
IROREST FCT 90 mg film-coated tablets
White to light blue colored, modified capsule-shaped, film-coated tablet engraved ‘APO’ on one side and ‘DF 90’ on the other side.
IROREST FCT 180 mg film-coated tablets
Blue to medium blue colored, Modified capsule-shaped, film-coated tablet engraved ‘APO’ on one side and ‘DF 180’ on the other side.
IROREST FCT 360 mg film-coated tablets
Blue to dark blue colored, Modified capsule-shaped film coated-tablet engraved ‘APO’ on one side and ‘DF 360’ on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>IROREST FCT is indicated for the treatment of chronic iron overload due to frequent blood transfusions (&ge;7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.<br />IROREST FCT is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:<br />&bull; in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (&ge;7 ml/kg/month of packed red blood cells) aged 2 to 5 years,<br />&bull; in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (&lt;7 ml/kg/month of packed red blood cells) aged 2 years and older,<br />&bull; in adult and paediatric patients with other anaemias aged 2 years and older.<br />IROREST FCT is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with IROREST FCT should be initiated and maintained by physicians experienced in the treatment of chronic iron overload.<br />Posology<br />Transfusional iron overload<br />It is recommended that treatment be started after the transfusion of approximately 20 units (about 100 ml/kg) of packed red blood cells (PRBC) or when there is evidence from clinical monitoring that chronic iron overload is present (e.g. serum ferritin &gt;1,000 &mu;g/l). Doses (in mg/kg) must be calculated and rounded to the nearest whole tablet size.<br />The goals of iron chelation therapy are to remove the amount of iron administered in transfusions and, as required, to reduce the existing iron burden.<br />Caution should be taken during chelation therapy to minimise the risk of overchelation in all patients (see section 4.4).<br />Medicines containing deferasirox are available as film-coated tablets and dispersible tablets marketed under different tradenames as generic alternatives to IROREST FCT. Due to different pharmacokinetic profiles, a 30% lower dose of IROREST FCT film-coated tablets is needed in comparison to the recommended dose for IROREST FCT dispersible tablets (see section 5.1).<br /><br /><strong>Table 1 Recommended doses for transfusional iron overload</strong><br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>&nbsp;</td><td>Film-coated tablets</td><td>Transfusions</td><td>&nbsp;</td><td>Serum ferritin</td></tr><tr><td>Starting dose</td><td>14 mg/kg/day</td><td>After 20 units (about 100 ml/kg) of PRBC</td><td>or</td><td>&gt;1,000 &mu;g/l</td></tr><tr><td>Alternative starting doses</td><td>21 mg/kg/day</td><td>&gt;14 ml/kg/month of PRBC (approx. &gt;4 units/month for an adult)</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>7 mg/kg/day</td><td>&lt;7 ml/kg/month of PRBC (approx. &lt;2 units/month for an adult)</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>For patients well managed on deferoxamine</td><td>One third of deferoxamine dose</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>Monitoring</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Monthly</td></tr><tr><td>Target range</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>500-1,000 &mu;g/l</td></tr><tr><td>Adjustment steps<br />(every 3-6 months)</td><td>Increase</td><td>&nbsp;</td><td>&nbsp;</td><td>&gt;2,500 &mu;g/l</td></tr><tr><td>&nbsp;</td><td>3.5 - 7 mg/kg/day<br />Up to 28 mg/kg/day</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>Decrease</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>3.5 - 7 mg/kg/day<br />In patients treated with doses &gt;21 mg/kg/day<br />- When target is reached</td><td>&nbsp;</td><td>&nbsp;</td><td>&le;2,500 &mu;g/l<br />500-1,000 &mu;g/l</td></tr><tr><td>Maximum dose</td><td>28 mg/kg/day</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>Consider</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&lt;500 &mu;g/l</td></tr><tr><td>interruption</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Starting dose<br />The recommended initial daily dose of IROREST FCT film-coated tablets is 14 mg/kg body weight.<br />An initial daily dose of 21 mg/kg of IROREST FCT film-coated tablets may be considered for patients who require reduction of elevated body iron levels and who are also receiving more than 14 ml/kg/month of packed red blood cells (approximately &gt;4 units/month for an adult).<br />An initial daily dose of 7 mg/kg of IROREST FCT film-coated tablets may be considered for patients who do not require reduction of body iron levels and who are also receiving less than 7 ml/kg/month of packed red blood cells (approximately &lt;2 units/month for an adult). The patient&#39;s response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).<br />For patients already well managed on treatment with deferoxamine, a starting dose of IROREST FCT film-coated tablets that is numerically one third that of the deferoxamine dose could be considered (e.g. a patient receiving 40 mg/kg/day of deferoxamine for 5 days per week (or equivalent) could be transferred to a starting daily dose of 14 mg/kg/day of IROREST FCT film-coated tablets). When this results in a daily dose less than 14 mg/kg body weight, the patient&#39;s response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).<br /><br />Dose adjustment<br />It is recommended that serum ferritin be monitored every month and that the dose of IROREST FCT film-coated tablets be adjusted, if necessary, every 3 to 6 months based on the trends in serum ferritin. Dose adjustments may be made in steps of 3.5 to 7 mg/kg and are to be tailored to the individual patient&#39;s response and therapeutic goals (maintenance or reduction of iron burden). In patients not adequately controlled with doses of 21 mg/kg (e.g. serum ferritin levels persistently above 2,500 &mu;g/l and not showing a decreasing trend over time), doses of up to 28 mg/kg may be considered. The availability of long-term efficacy and safety data from clinical studies conducted with IROREST FCT dispersible tablets used at doses above 30 mg/kg is currently limited (264 patients followed for an average of 1 year after dose escalation). If only very poor haemosiderosis control is achieved at doses up to 21 mg/kg (film-coated tablet dose equivalent of 30 mg/kg of dispersible tablets), a further increase (to a maximum of 28 mg/kg) may not achieve satisfactory control, and alternative treatment options may be considered. If no satisfactory control is achieved at doses above 21 mg/kg, treatment at such doses should not be maintained and alternative treatment options should be considered whenever possible. Doses above 28 mg/kg are not recommended because there is only limited experience with doses above this level (see section 5.1).<br />In patients treated with doses greater than 21 mg/kg, dose reductions in steps of 3.5 to 7 mg/kg should be considered when control has been achieved (e.g. serum ferritin levels persistently &le;2,500&nbsp;&mu;g/l and showing a decreasing trend over time). In patients whose serum ferritin level has reached the target (usually between 500 and 1,000 &mu;g/l), dose reductions in steps of 3.5 to 7 mg/kg should be considered to maintain serum ferritin levels within the target range and to minimise the risk of overchelation. If serum ferritin falls consistently below 500 &mu;g/l, an interruption of treatment should be considered (see section 4.4).<br /><br />Non-transfusion-dependent thalassaemia syndromes<br />Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] &ge;5 mg Fe/g dry weight [dw] or serum ferritin consistently &gt;800 &mu;g/l). LIC is the preferred method of iron overload determination and should be used wherever available. Caution should be taken during chelation therapy to minimise the risk of overchelation in all patients (see section 4.4).<br /><br />Medicines containing deferasirox are available as film-coated tablets and dispersible tablets marketed under different tradenames as generic alternatives to IROREST FCT. Due to different pharmacokinetic profiles, a 30% lower dose of IROREST FCT film-coated tablets is needed in comparison to the recommended dose for IROREST FCT dispersible tablets (see section 5.1).<br /><br /><strong>Table 2 Recommended doses for non-transfusion-dependent thalassaemia syndromes</strong><br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>&nbsp;</td><td>Film-coated tablets</td><td>Liver iron concentration (LIC)*</td><td>&nbsp;</td><td>Serum ferritin</td></tr><tr><td>Starting dose</td><td>7 mg/kg/day</td><td>&ge;5 mg Fe/g dw</td><td>or</td><td>&gt;800 &mu;g/l</td></tr><tr><td>Monitoring</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Monthly</td></tr><tr><td>Adjustment steps<br />(every 3-6 months)</td><td>Increase</td><td>&ge;7 mg Fe/g dw</td><td>or</td><td>&gt;2,000 &mu;g/l</td></tr><tr><td>&nbsp;</td><td>3.5 - 7 mg/kg/day</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>Decrease</td><td>&lt;7 mg Fe/g dw</td><td>or</td><td>&le;2,000 &mu;g/l</td></tr><tr><td>&nbsp;</td><td>3.5 - 7 mg/kg/day</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>Maximum dose</td><td>14 mg/kg/day<br />For adult patients</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>7 mg/kg/day<br />For paediatric patients<br />7 mg/kg/day</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>For both adult and paediatric patients</td><td>not assessed</td><td>and</td><td>&le;2,000 &mu;g/l</td></tr><tr><td>Interruption</td><td>&nbsp;</td><td>&lt;3 mg Fe/g dw</td><td>or</td><td>&lt;300 &mu;g/l</td></tr><tr><td>Retreatment</td><td>&nbsp;</td><td>Not recommended</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*LIC is the preferred method of iron overload determination.<br />Starting dose<br />The recommended initial daily dose of IROREST FCT film-coated tablets in patients with non-transfusion-dependent thalassaemia syndromes is 7 mg/kg body weight.<br />Dose adjustment<br />It is recommended that serum ferritin be monitored every month to assess the patient&#39;s response to therapy and to minimise the risk of overchelation (see section 4.4). After every 3 to 6 months of treatment, a dose increase in increments of 3.5 to 7 mg/kg should be considered if the patient&#39;s LIC is &ge;7 mg Fe/g dw, or if serum ferritin is consistently &gt;2,000 &mu;g/l and not showing a downward trend, and the patient is tolerating the medicinal product well. Doses of IROREST FCT film-coated tablets above 14 mg/kg are not recommended because there is no experience with doses above this level in patients with non-transfusion-dependent thalassaemia syndromes.<br />In both paediatric and adult patients in whom LIC was not assessed and serum ferritin is &le;2,000 &mu;g/l, dosing of IROREST FCT film-coated tablets should not exceed 7 mg/kg.<br />For patients in whom the dose was increased to &gt;7 mg/kg, dose reduction to 7 mg/kg or less is recommended when LIC is &lt;7 mg Fe/g dw or serum ferritin is &le;2,000 &mu;g/l.<br />Treatment cessation<br />Once a satisfactory body iron level has been achieved (LIC &lt;3 mg Fe/g dw or serum ferritin &lt;300 &mu;g/l), treatment should be stopped. There are no data available on the retreatment of patients who reaccumulate iron after having achieved a satisfactory body iron level and therefore retreatment cannot be recommended.<br />Special populations<br />Elderly patients (&ge;65 years of age)<br />The dosing recommendations for elderly patients are the same as described above. In clinical studies, elderly patients experienced a higher frequency of adverse reactions than younger patients&nbsp;(in particular, diarrhoea) and should be monitored closely for adverse reactions that may require a dose adjustment.<br /><br />Paediatric population<br />Transfusional iron overload:<br />The dosing recommendations for paediatric patients aged 2 to 17 years with transfusional iron overload are the same as for adult patients (see section 4.2). It is recommended that serum ferritin be monitored every month to assess the patient&#39;s response to therapy and to minimise the risk of overchelation (see section 4.4). Changes in weight of paediatric patients over time must be taken into account when calculating the dose.<br />In children with transfusional iron overload aged between 2 and 5 years, exposure is lower than in adults (see section 5.2). This age group may therefore require higher doses than are necessary in adults. However, the initial dose should be the same as in adults, followed by individual titration.<br />Non-transfusion-dependent thalassaemia syndromes:<br />In paediatric patients with non-transfusion-dependent thalassaemia syndromes, dosing of IROREST FCT film-coated tablets should not exceed 7 mg/kg. In these patients, closer monitoring of LIC and serum ferritin is essential to avoid overchelation (see section 4.4). In addition to monthly serum ferritin assessments, LIC should be monitored every three months when serum ferritin is &le;800 &mu;g/l.<br />Children from birth to 23 months:<br />The safety and efficacy of IROREST FCT in children from birth to 23 months of age have not been established. No data are available.<br />Patients with renal impairment<br />IROREST FCT has not been studied in patients with renal impairment and is contraindicated in patients with estimated creatinine clearance &lt;60 ml/min (see sections 4.3 and 4.4).<br /><br />Patients with hepatic impairment<br />IROREST FCT is not recommended in patients with severe hepatic impairment (Child-Pugh Class C). In patients with moderate hepatic impairment (Child-Pugh Class B), the dose should be considerably reduced followed by progressive increase up to a limit of 50% of recommended treatment dose for patients with normal hepatic function (see sections 4.4 and 5.2), and IROREST FCT must be used with caution in such patients. Hepatic function in all patients should be monitored&nbsp;before treatment, every 2 weeks during the first month and then every month (see section 4.4).<br /><br />Method of administration<br />For oral use.<br />The film-coated tablets should be swallowed whole with some water. For patients who are unable to swallow whole tablets, the film-coated tablets may be crushed and administered by sprinkling the full dose onto soft food, e.g. yogurt or apple sauce (pureed apple). The dose should be immediately and completely consumed, and not stored for future use.<br />The film-coated tablets should be taken once a day, preferably at the same time each day, and may be taken on an empty stomach or with a light meal (see sections 4.5 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Combination with other iron chelator therapies as the safety of such combinations has not been established (see section 4.5).
Patients with estimated creatinine clearance <60 ml/min.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><em><strong>Renal function</strong></em></u><br />Deferasirox has been studied only in patients with baseline serum creatinine within the age-appropriate normal range.<br />During clinical studies, increases in serum creatinine of &gt;33% on &ge;2 consecutive occasions, sometimes above the upper limit of the normal range, occurred in about 36% of patients. These were dose-dependent. About two-thirds of the patients showing serum creatinine increase returned below the 33% level without dose adjustment. In the remaining third the serum creatinine increase did not always respond to a dose reduction or a dose interruption. In some cases, only a stabilisation of the serum creatinine values has been observed after dose reduction. Cases of acute renal failure have been reported following post-marketing use of deferasirox (see section 4.8). In some post-marketing cases, renal function deterioration has led to renal failure requiring temporary or permanent dialysis.<br />The causes of the rises in serum creatinine have not been elucidated. Particular attention should therefore be paid to monitoring of serum creatinine in patients who are concomitantly receiving medicinal products that depress renal function, and in patients who are receiving high doses of deferasirox and/or low rates of transfusion (&lt;7 ml/kg/month of packed red blood cells or &lt;2 units/month for an adult). While no increase in renal adverse events was observed after dose escalation of IROREST FCT dispersible tablets to doses above 30 mg/kg in clinical studies, an increased risk of renal adverse events with film-coated tablet doses above 21 mg/kg cannot be excluded.<br />It is recommended that serum creatinine be assessed in duplicate before initiating therapy. Serum creatinine, creatinine clearance (estimated with the Cockcroft-Gault or MDRD formula in adults and with the Schwartz formula in children) and/or plasma cystatin C levels should be monitored prior to therapy, weekly in the first month after initiation or modification of therapy with IROREST FCT (including switch of formulation), and monthly thereafter. Patients with pre-existing renal conditions and patients who are receiving medicinal products that depress renal function may be more at risk of complications. Care should be taken to maintain adequate hydration in patients who develop diarrhoea or vomiting.<br />There have been post-marketing reports of metabolic acidosis occurring during treatment with deferasirox. The majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid-base imbalance is a known complication. Acid-base balance should be monitored as clinically indicated in these populations. Interruption of IROREST FCT therapy should be considered in patients who develop metabolic acidosis.<br />Post-marketing cases of severe forms of renal tubulopathy (such as Fanconi syndrome) and renal failure associated with changes in consciousness in the context of hyperammonaemic encephalopathy have been reported in patients treated with deferasirox, mainly in children. It is recommended that hyperammonaemic encephalopathy be considered and ammonia levels measured in patients who develop unexplained changes in mental status while on IROREST FCT therapy.<br /><br /><strong>Table 3 Dose adjustment and interruption of treatment for renal monitoring</strong><br /><br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>&nbsp;</td><td>Serum creatinine</td><td>&nbsp;</td><td>Creatinine clearance</td></tr><tr><td>Before initiation of therapy</td><td>Twice (2x)</td><td>and</td><td>&nbsp;</td></tr><tr><td>Contraindicated</td><td>&nbsp;</td><td>&nbsp;</td><td>&lt;60 ml/min</td></tr><tr><td>Monitoring</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>- First month after start of therapy or dose modification (including switch of formulation)</td><td>Weekly</td><td>and</td><td>Weekly</td></tr><tr><td>- Thereafter</td><td>Monthly</td><td>and</td><td>Monthly</td></tr><tr><td>Reduction of daily dose by 7 mg/kg/day (film-coated tablet formulation),&nbsp;if following renal parameters are observed at two consecutive visits and cannot be attributed to other causes</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>Adult patients</td><td>&gt;33% above pre-treatment average</td><td>and</td><td>Decreases &lt;LLN* (&lt;90 ml/min)</td></tr><tr><td>Paediatric patients</td><td>&gt; age appropriate ULN**</td><td>and/or</td><td>Decreases &lt;LLN* (&lt;90 ml/min)</td></tr><tr><td>After dose reduction, interrupt treatment, if</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>Adult and paediatric</td><td>Remains &gt;33% above pre-treatment average</td><td>and/or</td><td>Decreases &lt;LLN* (&lt;90 ml/min)</td></tr><tr><td>*LLN: lower limit of the normal range<br />**ULN: upper limit of the normal range</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Treatment may be reinitiated depending on the individual clinical circumstances.<br />Dose reduction or interruption may be also considered if abnormalities occur in levels of markers of renal tubular function and/or as clinically indicated:<br />&bull; Proteinuria (test should be performed prior to therapy and monthly thereafter)<br />&bull; Glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria (monitor as needed).<br />Renal tubulopathy has been mainly reported in children and adolescents with beta-thalassaemia treated with IROREST FCT.<br />Patients should be referred to a renal specialist, and further specialised investigations (such as renal biopsy) may be considered if the following occur despite dose reduction and interruption:<br />&bull; Serum creatinine remains significantly elevated and<br />&bull; Persistent abnormality in another marker of renal function (e.g. proteinuria, Fanconi Syndrome).<br /><br /><u><strong><em>Hepatic function</em></strong></u><br />Liver function test elevations have been observed in patients treated with deferasirox. Post-marketing cases of hepatic failure, some of which were fatal, have been reported. Severe forms associated with changes in consciousness in the context of hyperammonaemic encephalopathy, may occur in patients treated with deferasirox, particularly in children. It is recommended that hyperammonaemic encephalopathy be considered and ammonia levels measured in patients who develop unexplained changes in mental status while on IROREST FCT therapy. Care should be taken to maintain adequate hydration in patients who experience volume-depleting events (such as&nbsp;diarrhoea or vomiting), particularly in children with acute illness. Most reports of hepatic failure involved patients with significant comorbidities including pre-existing chronic liver conditions (including cirrhosis and hepatitis C) and multi-organ failure. The role of deferasirox as a contributing or aggravating factor cannot be excluded (see section 4.8).<br />It is recommended that serum transaminases, bilirubin and alkaline phosphatase be checked before the initiation of treatment, every 2 weeks during the first month and monthly thereafter. If there is a persistent and progressive increase in serum transaminase levels that cannot be attributed to other causes, IROREST FCT should be interrupted. Once the cause of the liver function test abnormalities has been clarified or after return to normal levels, cautious re-initiation of treatment at a lower dose followed by gradual dose escalation may be considered.<br />IROREST FCT is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) (see section 5.2).<br /><br /><strong>Table 4 Summary of safety monitoring recommendations</strong><br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Test</td><td>Frequency</td></tr><tr><td>Serum creatinine</td><td>In duplicate prior to therapy.<br />Weekly during first month of therapy or after dose modification (including switch of formulation).<br />Monthly thereafter.</td></tr><tr><td>Creatinine clearance and/or plasma cystatin C</td><td>Prior to therapy.<br />Weekly during first month of therapy or after dose modification (including switch of formulation).<br />Monthly thereafter</td></tr><tr><td>Proteinuria</td><td>Prior to therapy.<br />Monthly thereafter.</td></tr><tr><td>Other markers of renal tubular function (such as glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria)</td><td>As needed.</td></tr><tr><td>Serum transaminases, bilirubin, alkaline phosphatase</td><td>Prior to therapy.<br />Every 2 weeks during first month of therapy.<br />Monthly thereafter.</td></tr><tr><td>Auditory and ophthalmic testing</td><td>Prior to therapy.<br />Annually thereafter.</td></tr><tr><td>Body weight, height and sexual development</td><td>Prior to therapy.<br />Annually in paediatric patients.</td></tr></tbody></table><p><br />In patients with a short life expectancy (e.g. high-risk myelodysplastic syndromes), especially when co-morbidities could increase the risk of adverse events, the benefit of IROREST FCT might be limited and may be inferior to risks. As a consequence, treatment with IROREST FCT is not recommended in these patients.<br />Caution should be used in elderly patients due to a higher frequency of adverse reactions (in particular, diarrhoea).<br />Data in children with non-transfusion-dependent thalassaemia are very limited (see section 5.1). As a consequence, IROREST FCT therapy should be closely monitored to detect adverse reactions and to follow iron burden in the paediatric population. In addition, before treating heavily iron-overloaded children with non-transfusion-dependent thalassaemia with IROREST FCT, the physician should be aware that the consequences of long-term exposure in such patients are currently not known.<br /><br /><u><em><strong>Gastrointestinal disorders</strong></em></u><br />Upper gastrointestinal ulceration and haemorrhage have been reported in patients, including children and adolescents, receiving deferasirox. Multiple ulcers have been observed in some patients (see section 4.8). There have been reports of ulcers complicated with digestive perforation. Also, there have been reports of fatal gastrointestinal haemorrhages, especially in elderly patients who had haematological malignancies and/or low platelet counts. Physicians and patients should remain alert for signs and symptoms of gastrointestinal ulceration and haemorrhage during IROREST FCT therapy. In case of gastrointestinal ulceration or haemorrhage, IROREST FCT should be discontinued and additional evaluation and treatment must be promptly initiated. Caution should be exercised in patients who are taking IROREST FCT in combination with substances that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants and in patients with platelet counts below 50,000/mm3 (50 x 109/l) (see section 4.5).<br /><br /><u><em><strong>Skin disorders</strong></em></u><br />Skin rashes may appear during IROREST FCT treatment. The rashes resolve spontaneously in most cases. When interruption of treatment may be necessary, treatment may be reintroduced after&nbsp;resolution of the rash, at a lower dose followed by gradual dose escalation. In severe cases this reintroduction could be conducted in combination with a short period of oral steroid administration. Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported. If any SCAR is suspected, IROREST FCT should be discontinued immediately and should not be reintroduced. At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions, and be closely monitored.<br /><br /><u><em><strong>Hypersensitivity reactions</strong></em></u><br />Cases of serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been reported in patients receiving deferasirox, with the onset of the reaction occurring in the majority of cases within the first month of treatment (see section 4.8). If such reactions occur, IROREST FCT should be discontinued and appropriate medical intervention instituted. Deferasirox should not be reintroduced in patients who have experienced a hypersensitivity reaction due to the risk of anaphylactic shock (see section 4.3).<br /><br /><em><u><strong>Vision and hearing</strong></u></em><br />Auditory (decreased hearing) and ocular (lens opacities) disturbances have been reported (see section 4.8). Auditory and ophthalmic testing (including fundoscopy) is recommended before the start of treatment and at regular intervals thereafter (every 12 months). If disturbances are noted during the treatment, dose reduction or interruption may be considered.<br /><u><em><strong>Blood disorders</strong></em></u><br />There have been post-marketing reports of leukopenia, thrombocytopenia or pancytopenia (or aggravation of these cytopenias) and of aggravated anaemia in patients treated with deferasirox. Most of these patients had pre-existing haematological disorders that are frequently associated with bone marrow failure. However, a contributory or aggravating role cannot be excluded. Interruption of treatment should be considered in patients who develop unexplained cytopenia.<br /><u><em><strong>Other considerations</strong></em></u><br />Monthly monitoring of serum ferritin is recommended in order to assess the patient&#39;s response to therapy and to avoid overchelation (see section 4.2). Dose reduction or closer monitoring of renal and hepatic function, and serum ferritin levels are recommended during periods of treatments with high doses and when serum ferritin levels are close to the target range. If serum ferritin falls consistently below 500 &mu;g/l (in transfusional iron overload) or below 300 &mu;g/l (in non-transfusion-dependent thalassaemia syndromes), an interruption of treatment should be considered.<br />The results of the tests for serum creatinine, serum ferritin and serum transaminases should be recorded and regularly assessed for trends.<br />In two clinical studies, growth and sexual development of paediatric patients treated with deferasirox for up to 5 years were not affected (see section 4.8). However, as a general precautionary measure in the management of paediatric patients with transfusional iron overload, body weight, height and sexual development should be monitored prior to therapy and at regular intervals (every 12 months).<br />Cardiac dysfunction is a known complication of severe iron overload. Cardiac function should be monitored in patients with severe iron overload during long-term treatment with IROREST FCT.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of deferasirox in combination with other iron chelators has not been established. Therefore, it must not be combined with other iron chelator therapies (see section 4.3).<br />Interaction with food<br />The Cmax of deferasirox film-coated tablets was increased (by 29%) when taken with a high-fat meal. IROREST FCT film-coated tablets may be taken either on an empty stomach or with a light meal, preferably at the same time each day (see sections 4.2 and 5.2).<br />Agents that may decrease IROREST FCT systemic exposure<br />Deferasirox metabolism depends on UGT enzymes. In a healthy volunteer study, the concomitant administration of deferasirox (single dose of 30 mg/kg, dispersible tablet formulation) and the potent UGT inducer, rifampicin, (repeated dose of 600 mg/day) resulted in a decrease of deferasirox exposure by 44% (90% CI: 37% - 51%). Therefore, the concomitant use of IROREST FCT with potent UGT inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, ritonavir) may result in a decrease in IROREST FCT efficacy. The patient&#39;s serum ferritin should be monitored during and after the combination, and the dose of IROREST FCT adjusted if necessary.<br />Cholestyramine significantly reduced the deferasirox exposure in a mechanistic study to determine the degree of enterohepatic recycling (see section 5.2).<br />Interaction with midazolam and other agents metabolised by CYP3A4<br />In a healthy volunteer study, the concomitant administration of deferasirox dispersible tablets and&nbsp;midazolam (a CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17% (90% CI: 8% - 26%). In the clinical setting, this effect may be more pronounced. Therefore, due to a possible decrease in efficacy, caution should be exercised when deferasirox is combined with substances metabolised through CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive agents, bepridil, ergotamine).<br /><br />Interaction with repaglinide and other agents metabolised by CYP2C8<br />In a healthy volunteer study, the concomitant administration of deferasirox as a moderate CYP2C8 inhibitor (30 mg/kg daily, dispersible tablet formulation), with repaglinide, a CYP2C8 substrate, given as a single dose of 0.5 mg, increased repaglinide AUC and Cmax about 2.3-fold (90% CI [2.03-2.63]) and 1.6-fold (90% CI [1.42-1.84]), respectively. Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide, the concomitant use of deferasirox with repaglinide should be avoided. If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4). An interaction between deferasirox and other CYP2C8 substrates like paclitaxel cannot be excluded.<br />Interaction with theophylline and other agents metabolised by CYP1A2<br />In a healthy volunteer study, the concomitant administration of deferasirox as a CYP1A2 inhibitor (repeated dose of 30 mg/kg/day, dispersible tablet formulation) and the CYP1A2 substrate theophylline (single dose of 120 mg) resulted in an increase of theophylline AUC by 84% (90% CI: 73% to 95%). The single dose Cmax was not affected, but an increase of theophylline Cmax is expected to occur with chronic dosing. Therefore, the concomitant use of deferasirox with theophylline is not recommended. If deferasirox and theophylline are used concomitantly, monitoring of theophylline concentration and theophylline dose reduction should be considered. An interaction between deferasirox and other CYP1A2 substrates cannot be excluded. For substances that are predominantly metabolised by CYP1A2 and that have a narrow therapeutic index (e.g. clozapine, tizanidine), the same recommendations apply as for theophylline.<br /><br />Other information<br />The concomitant administration of deferasirox and aluminium-containing antacid preparations has not been formally studied. Although deferasirox has a lower affinity for aluminium than for iron, it is not recommended to take deferasirox tablets with aluminium-containing antacid preparations.<br />The concomitant administration of deferasirox with substances that have known ulcerogenic potential, such as NSAIDs (including acetylsalicylic acid at high dosage), corticosteroids or oral bisphosphonates may increase the risk of gastrointestinal toxicity (see section 4.4). The concomitant administration of deferasirox with anticoagulants may also increase the risk of gastrointestinal haemorrhage. Close clinical monitoring is required when deferasirox is combined with these&nbsp;substances.<br /><br />Concomitant administration of deferasirox and busulfan resulted in an increase of busulfan exposure (AUC), but the mechanism of the interaction remains unclear. If possible, evaluation of the pharmacokinetics (AUC, clearance) of a busulfan test dose should be performed to allow dose adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />No clinical data on exposed pregnancies are available for deferasirox. Studies in animals have shown some reproductive toxicity at maternally toxic doses (see section 5.3). The potential risk for humans is unknown.<br />As a precaution, it is recommended that IROREST FCT is not used during pregnancy unless clearly necessary.<br />IROREST FCT may decrease the efficacy of hormonal contraceptives (see section 4.5). Women of childbearing potential are recommended to use additional or alternative non-hormonal methods of contraception when using IROREST FCT.<br />Breast-feeding<br />In animal studies, deferasirox was found to be rapidly and extensively secreted into maternal milk. No effect on the offspring was noted. It is not known if deferasirox is secreted into human milk. Breast-feeding while taking IROREST FCT is not recommended.<br />Fertility<br />No fertility data is available for humans. In animals, no adverse effects on male or female fertility were found (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>IROREST FCT has minor influence on the ability to drive and use machines. Patients experiencing the uncommon adverse reaction of dizziness should exercise caution when driving or operating machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most frequent reactions reported during chronic treatment in clinical studies conducted with deferasirox dispersible tablets in adult and paediatric patients include gastrointestinal disturbances (mainly nausea, vomiting, diarrhoea or abdominal pain) and skin rash. Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years and in the elderly. These reactions are dose-dependent, mostly mild to moderate, generally transient and mostly resolve even if treatment is continued.<br />During clinical studies dose-dependent increases in serum creatinine occurred in about 36% of patients, though most remained within the normal range. Decreases in mean creatinine clearance have been observed in both paediatric and adult patients with beta-thalassemia and iron overload during the first year of treatment, but there is evidence that this does not decrease further in subsequent years of treatment. Elevations of liver transaminases have been reported. Safety monitoring schedules for renal and liver parameters are recommended. Auditory (decreased hearing) and ocular (lens opacities) disturbances are uncommon, and yearly examinations are also recommended (see section 4.4).<br />Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of IROREST FCT (see section 4.4).<br />Tabulated list of adverse reactions<br />Adverse reactions are ranked below using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br /><br /><strong>Table 5</strong><br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p>Not known:</p></td><td><p>Pancytopenia<sup>1</sup>, thrombocytopenia<sup>1</sup>, anaemia aggravated<sup>1</sup>, neutropenia<sup>1</sup></p></td></tr><tr><td colspan="2"><p><strong>Immune system disorders</strong></p></td></tr><tr><td><p>Not known:</p></td><td><p>Hypersensitivity reactions (including anaphylactic reactions and angioedema)<sup>1</sup></p></td></tr><tr><td colspan="2"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td><p>Not known:</p></td><td><p>Metabolic acidosis<sup>1</sup></p></td></tr><tr><td colspan="2"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Anxiety, sleep disorder</p></td></tr><tr><td colspan="2"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td><p>Common:</p></td><td><p>Headache</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Dizziness</p></td></tr><tr><td colspan="2"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Cataract, maculopathy</p></td></tr><tr><td><p>Rare:</p></td><td><p>Optic neuritis</p></td></tr><tr><td colspan="2"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Deafness</p></td></tr><tr><td colspan="2"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Laryngeal pain</p></td></tr><tr><td colspan="2"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p>Common:</p></td><td><p>Diarrhoea, constipation, vomiting, nausea, abdominal pain, abdominal distension, dyspepsia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Gastrointestinal haemorrhage, gastric ulcer (including multiple ulcers), duodenal ulcer, gastritis</p></td></tr><tr><td><p>Rare:</p></td><td><p>Oesophagitis</p></td></tr><tr><td><p>Not known:</p></td><td><p>Gastrointestinal perforation<sup>1</sup>, acute pancreatitis<sup>1</sup></p></td></tr><tr><td colspan="2"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td><p>Common:</p></td><td><p>Transaminases increased</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Hepatitis, cholelithiasis</p></td></tr><tr><td><p>Not known:</p></td><td><p>Hepatic failure<sup>1, 2</sup></p></td></tr><tr><td colspan="2"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p>Common:</p></td><td><p>Rash, pruritus</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Pigmentation disorder</p></td></tr><tr><td><p>Rare:</p></td><td><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td><p>Not known:</p></td><td><p>Stevens-Johnson syndrome<sup>1</sup>, hypersensitivity vasculitis<sup>1</sup>, urticaria<sup>1</sup>, erythema multiforme<sup>1</sup>, alopecia<sup>1</sup>, toxic epidermal necrolysis (TEN)<sup>1</sup></p></td></tr><tr><td colspan="2"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td><p>Very common:</p></td><td><p>Blood creatinine increased</p></td></tr><tr><td><p>Common:</p></td><td><p>Proteinuria</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Renal tubular disorder<sup>2</sup>&nbsp;(acquired Fanconi syndrome), glycosuria</p></td></tr><tr><td><p>Not known:</p></td><td><p>Acute renal failure<sup>1, 2</sup>, tubulointerstitial nephritis<sup>1</sup>, nephrolithiasis<sup>1</sup>, renal tubular necrosis<sup>1</sup></p></td></tr><tr><td colspan="2"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Pyrexia, oedema, fatigue</p></td></tr></tbody></table><p>1 Adverse reactions reported during post-marketing experience. These are derived from spontaneous reports for which it is not always possible to reliably establish frequency or a causal relationship to exposure to the medicinal product.<br />2 Severe forms associated with changes in consciousness in the context of hyperammonaemic encephalopathy have been reported.<br /><br />Description of selected adverse reactions<br />Gallstones and related biliary disorders were reported in about 2% of patients. Elevations of liver transaminases were reported as an adverse reaction in 2% of patients. Elevations of transaminases greater than 10 times the upper limit of the normal range, suggestive of hepatitis, were uncommon (0.3%). During post-marketing experience, hepatic failure, sometimes fatal, has been reported with deferasirox (see section 4.4). There have been post-marketing reports of metabolic acidosis. The majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid-base imbalance is a known complication (see section 4.4). Cases of serious acute pancreatitis were observed without documented underlying biliary conditions. As with other iron chelator treatment, high-frequency hearing loss and lenticular opacities (early cataracts) have been uncommonly observed in patients treated with deferasirox (see section 4.4).<br /><br />Creatinine clearance in transfusional iron overload<br />In a retrospective meta-analysis of 2,102 adult and paediatric beta-thalassaemia patients with&nbsp;transfusional iron overload treated with deferasirox dispersible tablets in two randomised and four open label studies of up to five years&#39; duration, a mean creatinine clearance decrease of 13.2% in adult patients (95% CI: -14.4% to -12.1%; n=935) and 9.9% (95% CI: -11.1% to -8.6%; n=1,142) in paediatric patients was observed during the first year of treatment. In 250 patients who were followed for up to five years, no further decrease in mean creatinine clearance levels was observed.<br />Clinical study in patients with non-transfusion-dependent thalassaemia syndromes<br />In a 1-year study in patients with non-transfusion-dependent thalassaemia syndromes and iron overload (dispersible tablets at a dose of 10 mg/kg/day), diarrhoea (9.1%), rash (9.1%), and nausea (7.3%) were the most frequent study drug-related adverse events. Abnormal serum creatinine and creatinine clearance values were reported in 5.5% and 1.8% of patients, respectively. Elevations of liver transaminases greater than 2 times the baseline and 5 times the upper limit of normal were reported in 1.8% of patients.<br />Paediatric population<br />In two clinical studies, growth and sexual development of paediatric patients treated with deferasirox for up to 5 years were not affected (see section 4.4).<br />Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years than in older patients.<br />Renal tubulopathy has been mainly reported in children and adolescents with beta-thalassaemia treated with deferasirox. In post-marketing reports, a high proportion of cases of metabolic acidosis occurred in children in the context of Fanconi syndrome.<br />Acute pancreatitis has been reported, particularly in children and adolescents.<br /><br /><br />To report any side effects:<br />Saudi Arabia:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>The National Pharmacovigilance Centre (NPC):<ul><li>Fax: +966-11-205-7662</li><li>SFDA Call Centre: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p><br /><br /><br />United Arab Emirates:<br />Pharmacovigilance &amp; Medical Device Section</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><ul><li>P.O.Box: 1853</li><li>Tel: 80011111</li><li>Email : pv@ede.gov.ae</li></ul>Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai</td></tr></tbody></table><p><br /><br />Other GCC Countries:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Please contact the relevant competent authority.</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vomiting. Hepatic and renal disorders have been reported, including cases of liver enzyme and creatinine increased with recovery after treatment discontinuation. An erroneously administered single dose of 90 mg/kg led to Fanconi syndrome which resolved after treatment.<br />There is no specific antidote for deferasirox. Standard procedures for management of overdose may be indicated as well as symptomatic treatment, as medically appropriate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Iron chelating agents, ATC code: V03AC03<br />Mechanism of action<br />Deferasirox is an orally active chelator that is highly selective for iron (III). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron, primarily in the faeces. Deferasirox has low affinity for zinc and copper, and does not cause constant low serum levels of these metals.<br />Pharmacodynamic effects<br />In an iron-balance metabolic study in iron-overloaded adult thalassaemic patients, deferasirox at daily doses of 10, 20 and 40 mg/kg (dispersible tablet formulation) induced the mean net excretion of 0.119, 0.329 and 0.445 mg Fe/kg body weight/day, respectively.<br /><br />Clinical efficacy and safety<br />Clinical efficacy studies were conducted with IROREST FCT dispersible tablets (referred to below as &#39;deferasirox&#39;). Compared to the deferasirox dispersible tablet formulation, the dose of the deferasirox film coated tablets is 30% lower than the dose of the deferasirox dispersible tablets, rounded to the nearest whole tablet (see section 5.2).<br />Deferasirox has been investigated in 411 adult (age &ge;16 years) and 292 paediatric patients (aged 2 to &lt;16 years) with chronic iron overload due to blood transfusions. Of the paediatric patients 52 were aged 2 to 5 years. The underlying conditions requiring transfusion included beta-thalassaemia, sickle cell disease and other congenital and acquired anaemias (myelodysplastic syndromes [MDS], Diamond-Blackfan syndrome, aplastic anaemia and other very rare anaemias).<br />Daily treatment with the deferasirox dispersible tablet formulation at doses of 20 and 30 mg/kg for one year in frequently transfused adult and paediatric patients with beta-thalassaemia led to reductions in indicators of total body iron; liver iron concentration was reduced by about -0.4 and -8.9 mg Fe/g liver (biopsy dry weight (dw)) on average, respectively, and serum ferritin was reduced by about -36 and -926 &mu;g/l on average, respectively. At these same doses the ratios of iron excretion: iron intake were 1.02 (indicating net iron balance) and 1.67 (indicating net iron removal), respectively. Deferasirox induced similar responses in iron-overloaded patients with other anaemias. Daily doses of 10 mg/kg (dispersible tablet formulation) for one year could maintain liver iron and serum ferritin levels and induce net iron balance in patients receiving infrequent transfusions or exchange transfusions. Serum ferritin assessed by monthly monitoring reflected changes in liver iron concentration indicating that trends in serum ferritin can be used to monitor response to therapy. Limited clinical data (29 patients with normal cardiac function at baseline) using MRI indicate that treatment with deferasirox 10-30 mg/kg/day (dispersible tablet formulation) for 1 year may also reduce levels of iron in the heart (on average, MRI T2* increased from 18.3 to 23.0 milliseconds).<br /><br />The principal analysis of the pivotal comparative study in 586 patients suffering from beta-thalassaemia and transfusional iron overload did not demonstrate non-inferiority of deferasirox dispersible tablets to deferoxamine in the analysis of the total patient population. It appeared from a post-hoc analysis of this study that, in the subgroup of patients with liver iron concentration &ge;7 mg Fe/g dw treated with deferasirox dispersible tablets (20 and 30 mg/kg) or deferoxamine (35 to &ge;50 mg/kg), the non-inferiority criteria were achieved. However, in patients with liver iron concentration &lt;7 mg Fe/g dw treated with deferasirox dispersible tablets (5 and 10 mg/kg) or deferoxamine (20 to 35 mg/kg), non-inferiority was not established due to imbalance in the dosing of the two chelators. This imbalance occurred because patients on deferoxamine were allowed to remain on their pre-study dose even if it was higher than the protocol specified dose. Fifty-six patients under the age of 6 years participated in this pivotal study, 28 of them receiving deferasirox dispersible tablets.<br />It appeared from preclinical and clinical studies that deferasirox dispersible tablets could be as active as deferoxamine when used in a dose ratio of 2:1 (i.e. a dose of deferasirox dispersible tablets that is numerically half of the deferoxamine dose). For deferasirox film-coated tablets, a dose ratio of 3:1 can be considered (i.e. a dose of deferasirox film-coated tablets that is numerically one third of the&nbsp;deferoxamine dose). However, this dosing recommendation was not prospectively assessed in the clinical studies.<br /><br />In addition, in patients with liver iron concentration &ge;7 mg Fe/g dw with various rare anaemias or sickle cell disease, deferasirox dispersible tablets up to 20 and 30 mg/kg produced a decrease in liver iron concentration and serum ferritin comparable to that obtained in patients with beta-thalassaemia.<br />A placebo-controlled randomised study was performed in 225 patients with MDS (Low/Int-1 risk) and transfusional iron overload. The results of this study suggest that there is a positive impact of deferasirox on event-free survival (EFS, a composite endpoint including non-fatal cardiac or liver events) and serum ferritin levels. The safety profile was consistent with previous studies in adult MDS patients.<br />In a 5-year observational study in which 267 children aged 2 to &lt;6 years (at enrollment) with transfusional haemosiderosis received deferasirox, there were no clinically meaningful differences in the safety and tolerability profile of IROREST FCT in paediatric patients aged 2 to &lt;6 years compared to the overall adult and older paediatric population, including increases in serum creatinine of &gt;33% and above the upper limit of normal on &ge;2 consecutive occasions (3.1%), and elevation of alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (4.3%). Single events of increase in ALT and aspartate aminotransferase were reported in 20.0% and 8.3%, respectively, of the 145 patients who completed the study.<br />In a study to assess the safety of deferasirox film-coated and dispersible tablets, 173 adult and paediatric patients with transfusion dependent thalassaemia or myelodysplastic syndrome were treated for 24 weeks. A comparable safety profile for film-coated and dispersible tablets was observed.<br />An open-label 1:1 randomised study was performed in 224 paediatric patients aged 2 to &lt;18 years old with transfusion-dependant anaemia and iron overload to evaluate treatment compliance, efficacy and safety of the deferasirox granule formulation compared to the dispersible tablet formulation. The majority of patients (142, 63.4%) in the study had beta-thalassemia major, 108 (48.2%) patients were na&iuml;ve to iron chelation therapy (ICT) (median age 2 years, 92.6% aged 2 to &lt;10 years) and 116 (51.8%) were ICT pre-treated (median age 7.5 years, 71.6% aged 2 to &lt;10 years) of whom 68.1% had previously received deferasirox. In the primary analysis performed in ICT-na&iuml;ve patients after 24 weeks of treatment, the compliance rate was 84.26% and 86.84% in the deferasirox dispersible tablets arm and in the deferasirox granules arm, respectively, with no statistically significant difference. Similarly, there was no statistically significant difference in mean changes from baseline in serum ferritin (SF) values between the two treatment arms (-171.52 &mu;g/l [95% CI: -517.40, 174.36] for dispersible tablets [DT] and 4.84 &mu;g/l [95% CI: -333.58, 343.27] for the granule formulation, difference between means [granules &ndash; DT] 176.36 &mu;g/l [95% CI: -129.00, 481.72], two sided p-value = 0.25). The study concluded that treatment compliance and efficacy were no different between deferasirox granules and deferasirox dispersible tablet arms at different time points (24 and 48 weeks). The safety profile was overall comparable between the granules and the dispersible tablet formulations.<br /><br />In patients with non-transfusion-dependent thalassaemia syndromes and iron overload, treatment with deferasirox dispersible tablets was assessed in a 1-year, randomised, double-blind, placebo-controlled study. The study compared the efficacy of two different deferasirox dispersible tablet regimens (starting doses of 5 and 10 mg/kg/day, 55 patients in each arm) and of matching placebo (56 patients). The study enrolled 145 adult and 21 paediatric patients. The primary efficacy parameter was the change in liver iron concentration (LIC) from baseline after 12 months of treatment. One of the secondary efficacy parameters was the change in serum ferritin between baseline and fourth quarter. At a starting dose of 10 mg/kg/day, deferasirox dispersible tablets led to reductions in indicators of total body iron. On average, liver iron concentration decreased by 3.80 mg Fe/g dw in patients treated with deferasirox dispersible tablets (starting dose 10 mg/kg/day) and increased by 0.38 mg Fe/g dw in patients treated with placebo (p&lt;0.001). On average, serum ferritin decreased by 222.0 &mu;g/l in patients treated with deferasirox dispersible tablets (starting dose 10 mg/kg/day) and increased by 115 &mu;g/l in patients treated with placebo (p&lt;0.001).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>IROREST FCT film-coated tablets demonstrate higher bioavailability compared to the IROREST FCT dispersible tablet formulation. After adjustment of the strength, the film-coated tablet formulation (360 mg strength) was equivalent to IROREST FCT dispersible tablets (500 mg strength) with respect to the mean area under the plasma concentration time curve (AUC) under fasting conditions. The Cmax was increased by 30% (90% CI: 20.3% - 40.0%); however a clinical exposure/response analysis revealed no evidence of clinically relevant effects of such an increase.<br /><br />Absorption<br />Deferasirox (dispersible tablet formulation) is absorbed following oral administration with a median time to maximum plasma concentration (tmax) of about 1.5 to 4 hours. The absolute bioavailability (AUC) of deferasirox (dispersible tablet formulation) is about 70% compared to an intravenous dose. The absolute bioavailability of the film-coated tablet formulation has not been determined. Bioavailability of deferasirox film-coated tablets was 36% greater than that with dispersible tablets.<br />A food-effect study involving administration of the film-coated tablets to healthy volunteers under fasting conditions and with a low-fat (fat content &lt;10% of calories) or high-fat (fat content &gt;50% of calories) meal indicated that the AUC and Cmax were slightly decreased after a low-fat meal (by 11% and 16%, respectively). After a high-fat meal, AUC and Cmax were increased (by 18% and 29%, respectively). The increases in Cmax due to the change in formulation and due to the effect of a high-fat meal may be additive and therefore, it is recommended that the film-coated tablets should be taken either on an empty stomach or with a light meal.<br /><br />Distribution<br />Deferasirox is highly (99%) protein bound to plasma proteins, almost exclusively serum albumin, and has a small volume of distribution of approximately 14 litres in adults.<br />Biotransformation<br />Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion. Deconjugation of glucuronidates in the intestine and subsequent reabsorption (enterohepatic recycling) is likely to occur: in a healthy volunteer study, the administration of cholestyramine after a single dose of deferasirox resulted in a 45% decrease in deferasirox exposure (AUC).<br />Deferasirox is mainly glucuronidated by UGT1A1 and to a lesser extent UGT1A3. CYP450-catalysed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). No inhibition of deferasirox metabolism by hydroxyurea was observed in vitro.<br /><br />Elimination<br />Deferasirox and its metabolites are primarily excreted in the faeces (84% of the dose). Renal excretion of deferasirox and its metabolites is minimal (8% of the dose). The mean elimination half-life (t1/2) ranged from 8 to 16 hours. The transporters MRP2 and MXR (BCRP) are involved in the biliary excretion of deferasirox.<br /><br />Linearity / non-linearity<br />The Cmax and AUC0-24h of deferasirox increase approximately linearly with dose under steady-state conditions. Upon multiple dosing exposure increased by an accumulation factor of 1.3 to 2.3.<br /><br />Characteristics in patients<br />Paediatric patients<br />The overall exposure of adolescents (12 to &le;17 years) and children (2 to &lt;12 years) to deferasirox after single and multiple doses was lower than that in adult patients. In children younger than 6 years old exposure was about 50% lower than in adults. Since dosing is individually adjusted according to response this is not expected to have clinical consequences.<br />Gender<br />Females have a moderately lower apparent clearance (by 17.5%) for deferasirox compared to males. Since dosing is individually adjusted according to response this is not expected to have clinical consequences.<br />Elderly patients<br />The pharmacokinetics of deferasirox have not been studied in elderly patients (aged 65 or older).<br /><br />Renal or hepatic impairment<br />The pharmacokinetics of deferasirox have not been studied in patients with renal impairment. The pharmacokinetics of deferasirox were not influenced by liver transaminase levels up to 5 times the upper limit of the normal range.<br />In a clinical study using single doses of 20 mg/kg deferasirox dispersible tablets, the average exposure was increased by 16% in subjects with mild hepatic impairment (Child-Pugh Class A) and by 76% in subjects with moderate hepatic impairment (Child-Pugh Class B) compared to subjects with normal hepatic function. The average Cmax of deferasirox in subjects with mild or moderate hepatic impairment was increased by 22%. Exposure was increased 2.8-fold in one subject with severe hepatic impairment (Child-Pugh Class C) (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential. The main findings were kidney toxicity and lens opacity (cataracts). Similar findings were observed in neonatal and juvenile animals. The kidney toxicity is considered mainly due to iron deprivation in animals that were not previously overloaded with iron.<br />Tests of genotoxicity in vitro were negative (Ames test, chromosomal aberration test) while deferasirox caused formation of micronuclei in vivo in the bone marrow, but not liver, of non-iron-loaded rats at lethal doses. No such effects were observed in iron-preloaded rats. Deferasirox was not carcinogenic when administered to rats in a 2-year study and transgenic p53+/- heterozygous mice in a 6-month study.<br />The potential for toxicity to reproduction was assessed in rats and rabbits. Deferasirox was not teratogenic, but caused increased frequency of skeletal variations and stillborn pups in rats at high doses that were severely toxic to the non-iron-overloaded mother. Deferasirox did not cause other effects on fertility or reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, indigotine Al Lake 12-14%, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Strength</strong></p></td><td><p><strong>Package Type</strong></p></td><td><p><strong>Description</strong></p></td><td><p><strong>Pack Size</strong></p></td></tr><tr><td rowspan="2"><p>90 mg</p></td><td><p>Alu-PVC</p><p>Blisters</p></td><td><p>Forming Foil: PVC Clear film 250 MIC 108 mm</p><p>Lidding Foil: Alu HSL foil 025 UM 105 mm coated white</p></td><td><p>30s</p></td></tr><tr><td><p>Alu-Alu Blisters</p></td><td><p>Forming Foil: Cold formable foil 60/50/25 128 MM</p><p>Lidding Foil: Alum HSL foil 025 128 mm (printed)</p></td><td><p>30s</p></td></tr><tr><td rowspan="2"><p>180 mg</p></td><td><p>Alu-PVC</p><p>Blisters</p></td><td><p>Forming Foil: PVC Clear film 250 MIC 132 mm</p><p>Lidding Foil: Alu HSL foil 025 UM 129 mm coated white</p></td><td><p>30s</p></td></tr><tr><td><p>Alu-Alu Blisters</p></td><td><p>Forming Foil: Alum foil silver 60/50/25 148 MM</p><p>Lidding Foil: Alum HSL foil 025 148 mm (printed)</p></td><td><p>30s</p></td></tr><tr><td rowspan="2"><p>360 mg</p></td><td><p>Alu-PVC</p><p>Blisters</p></td><td><p>Forming Foil: PVC Clear film 250 MIC 132 mm</p><p>Lidding Foil: Alu HSL foil 025 UM 129 mm coated white</p></td><td><p>30s</p></td></tr><tr><td><p>Alu-Alu Blisters</p></td><td><p>Forming Foil: Alum foil silver 60/50/25 148 MM</p><p>Lidding Foil: Alum HSL foil 025 148 mm (printed)</p></td><td><p>30s</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc
150 Signet Drive
Toronto, Ontario
Canada, M9L 1T9
Tel: 1-800-268-4623, Fax: 1-800-609-9444
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>